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 Abstract. Nowadays, numerous forms and questionnaires including those for patients with chronic liver disease 
are developed and successfully tested for almost every common nosology. The most widely used questionnaire is the 36-
Item Short Form Health Survey (SF-36). However, the disadvantage of the SF-36 includes insufficiently sensitive 
reduction in scales during deterioration in the patient’s condition. The Chronic Liver Disease Questionnaire (CLDQ) used 
in our study is better in this regard. The analysis of the results of interviewing showed significant differences among 
different groups. The average amount of received points was the largest in the control group, and the smallest in the 
experimental subgroup II (patients with cirrhosis). A significant difference was also noted in individual scales of the 
questionnaire. The signs of fatigue were almost identical in the control group and the experimental subgroup I, however, 
in the group with cirrhosis they were two times less. In this group people complaining of abdominal symptoms including 
bloating, abdominal pain and discomfort, and decrease in overall activity prevailed. The same group of patients reported 
the symptoms of anxiety, temper tantrum and sleep disturbances more often. People with chronic diffuse inflammation 
of the liver (the experimental subgroup I) differed significantly from healthy patients of the control group by 
characteristics reflecting anxiety levels, dietary habits, overall capacity, and abdominal symptoms to a somewhat lesser 
extent. 
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Problem statement and analysis of the recent research ` 
During study of chronic liver diseases and treatment of patients with chronic liver diseases it is necessary to 
evaluate the life quality of this group of patients objectively.  
The life quality is a main index of subjective experience of physical, emotional and mental well-being by a person 
[13]. Its study provides important information not only about actual self-esteem of health by the person himself or herself, 
but allows us to predict to some extent outcomes of the disease as well as to evaluate person’s daily and social activity 
[3]. Nowadays, numerous forms and questionnaires including those for patients with chronic liver disease are developed 
and successfully tested for almost every common nosology [9, 10, 11]. The most widely used questionnaire is the 36-
Item Short Form Health Survey (SF-36) developed by Ware JE, et al. in 1988 [12].  
However, the disadvantage of the SF-36 includes insufficiently sensitive reduction in scales during deterioration 
in the patient’s condition	especially those related to mental aspects. During continuous observation it also demonstrates 
insufficient reproducibility of the results [4]. The Chronic Liver Disease Questionnaire (CLDQ) used in our study is better 
in this regard. 
 
Materials and methods 
The CLDQ (Appendix 1) was developed at the Department of Gastroenterology (The Cleveland Clinic 
Foundation, USA) by Younossi et al. in 1999 as a specific instrument for examination of patients with chronic liver 
diseases [4]. It consists of 29 items which are grouped into 6 subscales: “Abdominal Symptoms” (AS) – questions No 1, 
5, 17; “Fatigue” (FA) – questions No 2, 4, 8, 11, 13; “Systemic Symptoms” (SS) – questions No 3, 6, 21, 23, 27; “Activity” 
(AC) – questions No 7, 9, 14; “Emotional Functioning” (EF) – questions No 10, 12, 15, 16, 19, 20, 24, 26; “Worries” 
(WO) – questions No 18, 22, 25, 28, 29. Each question can be rated on a 7-point scale with endpoints the most pronounced 
and the least pronounced. The minimum number of points is 29, the maximal one is 203. According to the results the 
questionnaire gives an opportunity to evaluate a range of indices of physical, mental and emotional spheres of the patient. 
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features of eating behavior, life and working conditions, social activity and emotional behavior we determined necessity 
of additional validation of the questionnaire. At first, the questionnaire was translated from English into Ukrainian by a 
professional translator. Then, the validation of the questionnaire was performed involving 50 practically healthy persons 
of young and middle age (the control group) and 120 persons of middle and old age with chronic liver diseases (the 
experimental group). The experimental group was additionally divided into 2 subgroups: subgroup I included patients 
with chronic diffuse inflammatory liver diseases (70 patients); subgroup II included patients with hepatic cirrhosis of 
different stages of compensation (50 patients). About 68% of patients of subgroup I suffered from nonalcoholic fatty liver 
disease, 22.9% of them suffered from chronic cholecystitis. The rest of patients suffered from chronic cholangitis (3.7%) 
and steatohepatitis (5.5%). 
The final mathematical and statistical data processing was performed using statistical software package “Statistica 
7.0” and “Microsoft Excel, 2010”. An unpaired two sample Student’s t-test with probability р±0.05 was performed. 
All groups were similar in gender characteristics: there were 42.0% of women in the control group and 41.4%, 
38.0% in subgroups I and II, respectively. In the control group the average age of examined patients was 28.5 years, in 
subgroup I it was 44.5 years, in subgroup II it was 49.5 years. Liver diseases were diagnosed by clinical, laboratory and 
functional signs according to National Recommendations and standard approaches. Patients with hepatic cirrhosis were 
additionally evaluated according to the Child-Pugh score. 64% (32 patients) were included into class А (the lowest 
mortality risk within a year), 22% (11 patients) were included into class В (the mortality risk within a year is moderate 
constituting about 20%), and 14% (7 patients) were included into class С (the mortality risk is the highest constituting 
about 50-60%) (Fig. 1.1). 
 
Fig. 1.1. Patients of subgroup II according to the Child-Pugh scale 
 
Results and discussion  
The analysis of the results of interviewing showed significant differences among different groups (Table 1).   
 
Table 1	
Distribution of  patients of the control and experimental subgroups according to subscales of the CLDQ in 











“Abdominal Symptoms” (AS) 17.5±2.5	 14.4±2.1	 8.4±1.6*	
“Fatigue” (FA) 27.2±1.8	 25.2±1.9	 12.6±1.5*¶	
“Systemic Symptoms” (SS) 30.8±2.7	 29.4±2.5	 13.5±2.0*¶	
“Activity” (AC) 17.5±2.6	 10.6±2.4*	 8.6±1.9*	
“Emotional Functioning” (EF) 35.4±3.6	 33.8±3.4	 28.6±2.9	
“Worries” (WO) 31.2±3.1	 24.6±2.9*	 15.8±2.1*	
	 	 	 	
Total 	 164.5±11.6	 122.8±8.4	 91.4±7.5*¶	
Notes:  
1. average number of collected points in subscales is indicated; 
2. * - standard deviation of the data between control and experimental groups, р±0.05.  
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The average amount of received points was the largest in the control group, and the smallest in the experimental 
subgroup II (patients with hepatic cirrhosis). In the control group this index was 164.5±11.6 points while in the 
experimental subgroup II it was practically twice less: 91.4±7.5 points. In the experimental subgroup I the average value 
was 122.8±8.4. A significant difference was also noted in individual scales of the questionnaire. The signs of fatigue were 
almost identical in the control group and the experimental subgroup I (27.2±1.8 and 25.2±1.9, respectively), however, in 
the group with cirrhosis they were twice lower (12.6±1.5 points). In this group people complaining of abdominal 
symptoms including bloating, abdominal pain and discomfort, and decrease in overall activity prevailed. The same group 
of patients reported the symptoms of anxiety, temper tantrum and sleep disturbances more often. 
Patients with chronic diffuse inflammation of the liver (the experimental subgroup I) differed significantly from 
healthy patients of the control group by characteristics reflecting anxiety levels, dietary habits, overall capacity, and 
abdominal symptoms to a somewhat lesser extent. Patients of the control group scored in average 31.2±3.1 points when 
rating the subscale “Worries” while patients of the experimental subgroup I scored only 24.6±2.9 points. It is necessary 
to note that patients of the experimental subgroup II scored only 15.8±2.1 points. There was practically no difference 
between the control and experimental subgroup I in rating the subscales “Fatigue”, “Systemic Symptoms” and “Emotional 
Functioning”. Patients of both experimental subgroups were also similar in rating the subscale “Emotional Functioning”, 
33.8±3.4 points and 28.6±2.9 points respectively.  
 
Conclusions 
Thus, the results of our research confirmed high value of Chronic Liver Disease Questionnaire for grading patients 
with different degrees of severity of end-stage liver disease in patients with cirrhosis, as well as diagnostics of its early 
damages, such as hepatic steatosis. The fact that the results of the questionnaire do not depend on the age of examined 
patients is an additional advantage. The disadvantage includes not always unambiguous characteristics of emotional 
sphere that can be associated with different psychological status of this group of patients and high levels of depression in 
patients with hepatic encephalopathy, and requires an additional evaluation by specialists. 
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Child-Pugh classification of severity of liver disease 
Index 	 1 point	 2 points	 3 points *	 Units 	
Total bilirubin	 <34	 34-50	 >50	 mcmol/L	
Serum albumin	 >35	 28-35	 <28	 g/L	
МНС	 <1.7	 1.7-2.2	 >2.2	 -	
Ascites	 none	 is corrected	 refractory	 -	
Hepatic 
encephalopathy	
none	 І-ІІ (is corrected)	 III-IV (refractory)	 -	
*  – 3  points: the most severe damage 
 
Appendix 2 






5-6	 А	 100%	 85%	
7-9	 В	 81%	 57%	
10-15	 С	 45%	 35%	
*  – calculated from the sum collected in the subscale 
 
	
	
